Figure 3.
Improvement of endothelial thrombin generation in DOAC patient plasma by superFVa. Thrombin generation was performed in plasma from patients on chronic anticoagulation with DOACs in the presence of EA.hy926 endothelial cells (○) and in the absence of cells (□). Thrombin generation in the absence of cells was initiated by 0.4 pM tissue factor and 10 μM phospholipid vesicles (PC/PS/PE 40/20/40). Shown are the endogenous thrombin potential (ETP) (A,C,E) and the lag time (B,D,F) of thrombin generation in the presence or absence of antibodies (50 μg/mL) against (A)PC (αPC; C1) or superFVa (20 nM) of patients on chronic anticoagulation with apixaban (A-B), rivaroxaban (C-D) , and dabigatran (E-F).

Improvement of endothelial thrombin generation in DOAC patient plasma by superFVa. Thrombin generation was performed in plasma from patients on chronic anticoagulation with DOACs in the presence of EA.hy926 endothelial cells (○) and in the absence of cells (□). Thrombin generation in the absence of cells was initiated by 0.4 pM tissue factor and 10 μM phospholipid vesicles (PC/PS/PE 40/20/40). Shown are the endogenous thrombin potential (ETP) (A,C,E) and the lag time (B,D,F) of thrombin generation in the presence or absence of antibodies (50 μg/mL) against (A)PC (αPC; C1) or superFVa (20 nM) of patients on chronic anticoagulation with apixaban (A-B), rivaroxaban (C-D) , and dabigatran (E-F).

Close Modal

or Create an Account

Close Modal
Close Modal